Jen Jen Yeh

Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Supplementary Data Figure 1. PDX show high correlation within the same patient line across different runs compared to different patient lines on the same run. Supplementary Data Figure 2. Mouse kinase expression is not line specific and does not associate with tumor molecular subtype. Supplementary Data Figure 3. Molecular subtyping in PDX model recapitulates basal-like and classical tumor specific subtypes. Supplementary Data Figure 4. Subtype specific kinase expression is associated with gene expression in PDX tumors. Supplementary Data Figure 5. Kinase expression from patients reflects the PDAC PDX kinome. Supplementary Data Figure 6. Overall survival (OS) and treatment response of patients who received EGFR inhibitors.

Year:

2025

Effective therapies for pancreatic ductal adenocarcinoma (PDAC) have been largely elusive. In this study, we perform multiplexed kinase inhibitor bead mass spectrometry on 102 patient-derived xenografts derived from 14 unique primary PDACs to define the tumor-intrinsic kinome landscape. Our findings uncover three kinome subgroups making up two tumor-intrinsic kinome subtypes that we call kinotypes. The kinotypes show enrichment of different kinase classes and recapitulate previously described molecular subtypes, basal-like and classical. The kinotype characterizing basal-like tumors shows enrichment of receptor tyrosine kinases, whereas the kinotype characterizing classical tumors is enriched in understudied kinases involved in Wnt signaling and immune pathways. We validate our findings in two clinical trials and show that only patients with basal-like tumors derive significant benefit from EGFR inhibitors. Our results provide a comprehensive tumor-intrinsic kinome landscape of PDAC that strongly supports actionable kinotype-specific kinase targets and provides a roadmap for kinase inhibitor therapy in PDAC. Significance: We provide a comprehensive tumor-intrinsic kinome landscape that provides a roadmap for the use of kinase inhibitors in PDAC treatment approaches.

Year:

2025

Background and Objectives Studies show that new onset diabetes mellitus (DM) (NOD) predates the diagnosis of PDAC by up to 2 years. Two tumor‐intrinsic molecular subtypes of PDAC that are prognostic and predictive of chemotherapy response have been described and validated. We hypothesize that patients with NOD may have different molecular subtypes and prognoses. Methods This is a single‐institution study of patients who underwent resection for PDAC from 2009 to 2022 with de‐identified samples available for sequencing. Demographic and clinical factors were examined using bivariate and multivariate analysis. Results A total of 97 patients met inclusion criteria: 70 with no history of DM, 11 with longstanding DM (> 2 years), and 16 with NOD. The demographics between groups were overall similar. After controlling for age, sex, race, BMI, and tobacco history, NOD was not a significant predictor of PDAC subtype. There were no survival differences between groups. Transcriptomic analysis suggests the upregulation of inflammatory and immune activation and regulation pathways in NOD. Conclusions As continued interest in NOD and PDAC mounts, we are the first to examine if NOD may be associated with molecular subtypes and outcomes. Further investigation into the underlying pathophysiology of the NOD group is still needed.

Year:

2024

A noticeable characteristic of pancreatic ductal adenocarcinoma (PDAC) tumors is a dense tumor microenvironment with abundant and dense, desmoplastic stroma woven tightly with both cellular and matrix components. The high stromal density is associated with higher intratumor pressures which, until the last decade, was largely assumed to be tumor protective, confirmed by early studies demonstrating that altering the stroma was effective in genetically engineered models of PDAC. However, clinical trials using these approaches have been disappointing. There is increasing recognition that stroma heterogeneity is much greater than initially thought with an explosion of investigation into cancer-associated fibroblast (CAF) subpopulations led by experimental and single-cell transcriptomic studies. This review summarizes and attempts to harmonize the current transcriptomic data of CAF subpopulations. Understanding the heterogeneity of CAFs, the matrix, and other tumor microenvironment features will be critical to developing effective therapeutic approaches. Identifying model systems that best recapitulate the clinical behavior and treatment response of human PDAC will be important. Examining subpopulations as defined by clinical outcome will remain a critical step in defining clinically impactful CAF subtypes in larger clinical cohorts. The future of precision oncology in PDAC will depend on the integration of precision tumor epithelial and precision stroma approaches.

Year:

2024

An explosion of technological advances has facilitated the unprecedented use of liquid biopsy methods to isolate and interrogate circulating tumor DNA for precision oncology approaches. Liquid biopsy samples are not isolated to plasma but include bodily fluids such as urine and bile. In this issue, Ohyama et al. present a prospective study of patients with biliary tract cancers who underwent cell‐free DNA (cfDNA) isolation from bile and plasma, further demonstrating the feasibility and promise of bile cfDNA for biliary tract malignancies.

Year:

2023

Collaborators (5)

Michael East

Research Assistant Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Volker Heinemann

Professor, M.D

Ludwig-Maximilians-Universität München

GERMANY
View details

Steffen Ormanns

Medical University of Innsbruck

AUSTRIA
View details

Xianlu Laura Peng

University of North Carolina at Chapel Hill

UNITED STATES
View details

Shawn Gomez

Peter Tong Department Chair and Professor

University of Wisconsin-Madison

UNITED STATES
View details